Migraine Tied to Behavioral, Psychological Factors
TUESDAY, Oct. 4, 2022 (HealthDay News) — Even in individuals without psychiatric comorbidities, specific behavioral and psychological factors are associated with migraine, according to a study published online Aug. 26 in The Journal of Headache and P…
Learn MoreApremilast May Offer Cardiometabolic Benefit in Psoriasis Patients
TUESDAY, Oct. 4, 2022 (HealthDay News) — For patients with moderate-to-severe psoriasis, apremilast appears to have a neutral association with aortic vascular inflammation, generally beneficial associations with certain cardiometabolic biomarkers, an…
Learn MoreUse of Living-Donor Liver Transplantation Low in U.S., U.K., Canada
TUESDAY, Oct. 4, 2022 (HealthDay News) — Utilization of living-donor liver transplantation (LDLT) is low in the United States, Canada, and the United Kingdom, but long-term survival is high, according to a study published online Sept. 25 in the Journ…
Learn MoreRituximab Studied as Add-On Therapy for New-Onset Myasthenia Gravis
TUESDAY, Oct. 4, 2022 (HealthDay News) — A single infusion of rituximab early after the onset of generalized myasthenia gravis improves outcomes at 16 weeks, according to a study published online Sept. 19 in JAMA Neurology.Fredrik Piehl, M.D., Ph.D.,…
Learn MoreNifedipine ER Helps Control BP in Severe Preeclampsia
MONDAY, Oct. 3, 2022 (HealthDay News) — For individuals with preeclampsia with severe features, extended-release nifedipine reduces the receipt of intrapartum acute hypertensive therapy, according to a study published online Oct. 3 in Hypertension.Er…
Learn MoreAre Your Hands Just Dry, Or Is It Eczema?
SUNDAY, Oct. 2, 2022 (HealthDay News) — Sometimes that irritated skin on your hands is more than simple dryness. Hand eczema could be the culprit, with painful dry and itchy skin on all or part of the hand and fingers.”If your hands are extremely dry…
Learn MoreFDA Approves Dupixent for Prurigo Nodularis
FRIDAY, Sept. 30, 2022 (HealthDay News) — The U.S. Food and Drug Administration approved Dupixent (dupilumab) as the first treatment for adults with prurigo nodularis, according to Regeneron Pharmaceuticals.Prurigo nodularis, a chronic, debilitating …
Learn MoreFDA Approves Dupixent for Prurigo Nodularis
FRIDAY, Sept. 30, 2022 (HealthDay News) — The U.S. Food and Drug Administration approved Dupixent (dupilumab) as the first treatment for adults with prurigo nodularis, according to Regeneron Pharmaceuticals.Prurigo nodularis, a chronic, debilitating …
Learn MoreFDA Approves Dupixent for Prurigo Nodularis
FRIDAY, Sept. 30, 2022 (HealthDay News) — The U.S. Food and Drug Administration approved Dupixent (dupilumab) as the first treatment for adults with prurigo nodularis, according to Regeneron Pharmaceuticals.Prurigo nodularis, a chronic, debilitating …
Learn MoreAcute Respiratory Illness Due to EV-D68 Increased in Late Summer 2022
THURSDAY, Sept. 29, 2022 (HealthDay News) — In late summer 2022, for children and adolescents, there was an increase in acute respiratory illness (ARI) resulting from enterovirus (EV)-D68 in the United States, according to research published in the …
Learn More